Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- AUTHORS Pemmaraju, et al
- Programs OPN-2853
2019
PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma
- AUTHORS Erkes, et al
- Programs OPN-51107
Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer
- AUTHORS Zhu, et al
- Programs OPN-51107
The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner
- AUTHORS Erkes, et al
- Programs OPN-51107
Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma
- AUTHORS Ambrosini, et al
- Programs OPN-51107
Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma
- AUTHORS Chua, et al
- Programs OPN-51107
BET Inhibition Modifies Melanoma Infiltrating T Cells and Enhances Response to PD-L1 Blockade
- AUTHORS Nikbakht, et al
- Programs OPN-51107